Stonebrook Private Inc. Buys 2,175 Shares of DexCom, Inc. (NASDAQ:DXCM)

Stonebrook Private Inc. boosted its stake in DexCom, Inc. (NASDAQ:DXCM) by 97.7% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,402 shares of the medical device company’s stock after acquiring an additional 2,175 shares during the quarter. Stonebrook Private Inc.’s holdings in DexCom were worth $499,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Chicago Capital LLC lifted its holdings in shares of DexCom by 0.3% in the second quarter. Chicago Capital LLC now owns 677,324 shares of the medical device company’s stock valued at $76,795,000 after purchasing an additional 1,842 shares in the last quarter. Private Advisor Group LLC lifted its stake in DexCom by 9.1% in the 2nd quarter. Private Advisor Group LLC now owns 10,710 shares of the medical device company’s stock valued at $1,214,000 after acquiring an additional 891 shares in the last quarter. New York Life Investment Management LLC boosted its position in DexCom by 3.8% during the 2nd quarter. New York Life Investment Management LLC now owns 60,544 shares of the medical device company’s stock worth $6,864,000 after acquiring an additional 2,211 shares during the last quarter. Arcadia Investment Management Corp MI grew its stake in shares of DexCom by 8,075.0% during the 2nd quarter. Arcadia Investment Management Corp MI now owns 1,635 shares of the medical device company’s stock worth $185,000 after acquiring an additional 1,615 shares in the last quarter. Finally, Arizona State Retirement System raised its holdings in shares of DexCom by 0.8% in the second quarter. Arizona State Retirement System now owns 111,763 shares of the medical device company’s stock valued at $12,672,000 after purchasing an additional 886 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms recently weighed in on DXCM. Piper Sandler reaffirmed an “overweight” rating and issued a $90.00 target price on shares of DexCom in a research report on Monday, August 26th. Royal Bank of Canada dropped their target price on DexCom from $165.00 to $145.00 and set an “outperform” rating on the stock in a report on Friday, July 26th. Redburn Atlantic began coverage on DexCom in a research note on Thursday, May 30th. They issued a “neutral” rating and a $130.00 price target for the company. Robert W. Baird upped their price objective on DexCom from $80.00 to $82.00 and gave the stock a “neutral” rating in a research note on Monday, August 5th. Finally, UBS Group cut their price objective on DexCom from $163.00 to $95.00 and set a “buy” rating for the company in a report on Friday, July 26th. Seven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $112.25.

Insiders Place Their Bets

In related news, EVP Michael Jon Brown sold 652 shares of the stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $69.55, for a total transaction of $45,346.60. Following the sale, the executive vice president now owns 66,249 shares in the company, valued at approximately $4,607,617.95. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other DexCom news, EVP Michael Jon Brown sold 652 shares of the business’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $69.55, for a total transaction of $45,346.60. Following the completion of the transaction, the executive vice president now owns 66,249 shares of the company’s stock, valued at $4,607,617.95. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Sadie Stern sold 427 shares of the firm’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $115.05, for a total transaction of $49,126.35. Following the completion of the sale, the executive vice president now owns 75,877 shares in the company, valued at $8,729,648.85. The disclosure for this sale can be found here. Insiders have sold a total of 3,483 shares of company stock worth $369,052 in the last quarter. Corporate insiders own 0.30% of the company’s stock.

DexCom Stock Performance

NASDAQ:DXCM traded down $0.44 during mid-day trading on Friday, hitting $68.61. 3,698,941 shares of the stock were exchanged, compared to its average volume of 3,793,475. The firm’s 50-day simple moving average is $86.66 and its 200 day simple moving average is $112.94. The stock has a market capitalization of $27.29 billion, a price-to-earnings ratio of 44.26, a price-to-earnings-growth ratio of 2.15 and a beta of 1.18. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.48 and a current ratio of 2.82.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The company had revenue of $1 billion during the quarter, compared to analysts’ expectations of $1.04 billion. During the same quarter in the previous year, the business posted $0.34 earnings per share. DexCom’s quarterly revenue was up 15.3% on a year-over-year basis. As a group, equities analysts anticipate that DexCom, Inc. will post 1.69 EPS for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.